Related Experiment Video
Updated: Feb 23, 2026

Formulating and Characterizing an Exosome-based Dopamine Carrier System
Published on: April 4, 2022
Exosome-mediated neuroprotection in vascular dementia: Mechanisms, molecular pathways, and therapeutic prospects
Farzaneh Fazli1, Samin Davoody2, Nicole Vissers3
1Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran; Department of Anatomical Sciences, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Abstract:
Exosomes, a specialized class of extracellular vesicles, exhibit significant therapeutic potentials for neurological disorders, in particular for vascular dementia (VaD). VaD is the second most common form of dementia, characterized by cognitive and behavioral impairments. VaD is often linked to hippocampal damage resulting from its vulnerable vascular structure, which disrupts memory formation and retrieval. Secreted by various cell types within the central nervous system, exosomes mediate intercellular communication by transporting bioactive molecules. Growing evidence indicates that exosomes enhance synaptic plasticity, modulate neuroinflammation, inhibit apoptosis, and promote angiogenesis, supporting their therapeutic potentials in VaD. Given the urgent need for effective treatments and the unique ability of exosomes to cross the blood-brain barrier (BBB) and deliver multi-targeted therapies, research in this field is critically important. It offers a viable pathway toward the development of disease-modifying interventions for a condition that is currently managed primarily through symptomatic treatment. This review summarizes current knowledge on the functions of exosomes in the central nervous system, explores recent advances in exosome-based strategies for VaD, and discusses ongoing challenges and future directions for their clinical translation.
Related Concept Videos
Alzheimer's Disease: Treatment
The Blood-brain Barrier
Overview of Exosomes
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

